On Thursday, Halcon Resources Corp (NYSE:HK)’s shares inclined 349.52% to $1.44. Halcon Resources Corp (NYSE:HK) is now worth about $870.24 million. The share price has made a -35.65% loss in the past 5 days and has lost -83.84% since 2015 kicked off. Analysts are forecasting EPS growth of -2.99% for next fiscal year and 25.00% growth in the next 5 years. The stock trades with a beta of 2.06. The stock price is below by -72.49% as contrast to the average price over the last 200 days. The company has 71.60% gross margins.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
T-Mobile US Inc (NASDAQ:TMUS)’s shares dropped -1.15% to $39.67. With its recent share price change, TMUS market value has reached roughly $32.37 billion. Its most recent quarter balance sheet showed the company is standing at a 1.40 current ratio and possess -1.52 as debt to equity ratio. The company has a Profit Margin (ttm) of 1.60% and has 50.90% gross margins. The operating profit margin is 5.20%. The stock’s performance in 1 month is 3.33% and its volatility for the same period is 2.88%.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets. It also provides wireless devices, such as smartphones, tablets, and other mobile communication devices, in addition to accessories, which are manufactured by various suppliers. It offers services, devices, and accessories through its owned and operated retail stores, in addition to through its Websites.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)‘s shares dipped -0.47% to $8.40. The last trading range of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ranges between $8.31 and $5.62. The EPS of the company stands at $-1.04. The 52-week range shows that the stock reached higher at $14.93 while its lower range is $4.70 in the last 52-weeks. The average volume of the company is at 3.09 million with the Outstanding Shares of 130.89 million. The market capitalization of the company is $1.10 billion. The Beta of the company stands at 1.54 with the RSI (Relative Strength Index) of 30.43.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
